Muscle Pharm Corp (MSLP) 6.3000 $MSLP MusclePharm

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Muscle Pharm Corp (MSLP) 6.3000 $MSLP

MusclePharm Schedules Fiscal 2013 Fourth Quarter and Full Year Financial Results Press Release and Conference Call for March 31, 2014
Marketwire - Mon Mar 24, 3:30PM CDT
MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, will report its financial results for the fourth quarter and full year ended Dec. 31, 2013 on Monday, March 31, 2014, prior to market open. The company will also conduct a conference call at 11 a.m. Eastern Time/8 a.m. Pacific Time on the same day to discuss the results.

USA Wrestling Names MusclePharm as Its Exclusive Official Nutritional Supplement Provider
Marketwire - Thu Mar 06, 7:15AM CST
USA Wrestling, the national governing body for wrestling in the United States, has signed MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, as its exclusive official nutritional supplement provider.

The Arnold Schwarzenegger Blueprint by MusclePharm Debuts at BodyBuilding.com
Marketwire - Thu Feb 27, 7:04AM CST
MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, today announced the launch of The Arnold Schwarzenegger(TM) Blueprint at BodyBuilding.com leading up to the annual Arnold Sports Festival in Columbus, Ohio from Feb. 27 - March 2, 2014.

MusclePharm Sports Science Institute Hosts RockTape Fascial Movement Taping Workshop
Marketwire - Wed Feb 26, 12:30PM CST
MusclePharm Corporation, a leading international, award-winning sports nutrition company, recently hosted a RockTape Fascial Movement Taping workshop to provide training and certification for kinesiology taping techniques. Fascial Movement Taping is a technique based on muscles acting as a chain to create efficient, fluid patterns.

MusclePharm CEO Issues Update Letter to Shareholders
Marketwire - Wed Jan 29, 8:01AM CST
MusclePharm Corporation (OTCQB: MSLP), a leading, award-winning sports nutrition company, today issued the following letter to shareholders from its Chairman and CEO, Brad Pyatt:

MusclePharm Corporation acquires BioZone Pharmaceuticals' assets
M2 - Tue Jan 07, 5:52AM CST
Sports nutrition company MusclePharm Corporation (OTCQB:MSLP) revealed on Monday the completion of the acquisition of essentially all assets of BioZone Pharmaceuticals Inc (OTCBB: BZNE) and its subsidiaries, for 1.2m shares of MusclePharm stock.

MusclePharm Completes Acquisition of Substantially All Assets of BioZone Pharmaceuticals
Marketwire - Mon Jan 06, 7:31AM CST
MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, today announced that it has completed the acquisition of essentially all assets of BioZone Pharmaceuticals, Inc. (OTCBB: BZNE) and its subsidiaries, for 1.2 million shares of MusclePharm stock.

MusclePharm Names PondelWilkinson as Investor Relations Counsel
Marketwire - Tue Dec 31, 7:30AM CST
MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, today announced that it has retained PondelWilkinson Inc. as investor relations counsel.

BioZone Pharmaceuticals, Inc. Completes Balance Sheet Enhancement
Marketwire - Tue Dec 24, 7:00AM CST
BioZone Pharmaceuticals, Inc. (OTCBB: BZNE) announced today that it has completed an enhancement of its balance sheet by eliminating remaining outstanding convertible notes. In the recent transaction, holders of convertible notes with approximately $2.5 million of principal and accrued interest exchanged their securities for shares of common stock. OPKO Health Inc. (NYSE: OPK), a principal shareholder of BioZone Pharmaceuticals and one of the note holders that converted its notes, expressed the view through its Chairman and CEO, Dr. Phillip Frost, that it is optimistic that the planned acquisition of Cocrystal Discovery will enhance shareholder value and enhance BioZone's future prospects as a high growth biotech company.

MusclePharm Announces New $5 Million Share Repurchase Program
Marketwire - Tue Dec 10, 9:01AM CST
MusclePharm Corporation (OTCQB: MSLP) (the "Company"), a leading international, award-winning sports nutrition company, announced that its Board of Directors has approved a new 1 year, $5 million program to repurchase shares of MusclePharm's common stock.

BioZone Pharmaceuticals, Inc. Enhances Balance Sheet
Marketwire - Mon Dec 02, 7:46AM CST
BioZone Pharmaceuticals, Inc. (OTCQB: BZNE) announced today that it has enhanced its balance sheet significantly by eliminating outstanding convertible preferred stock. In the recent transaction, holders of convertible preferred stock, with a stated value of $3.5 million and a 10% dividend, exchanged their securities for shares of common stock. Key holders expressed the view that the recently announced merger with Cocrystal Discovery, Inc. is a significant positive development for the Company.

Ultimate Fighting Championship® (UFC), MusclePharm® Renew Partnership
PR Newswire - Mon Dec 02, 6:30AM CST
The Ultimate Fighting Championship® announced a multi-year renewal with MusclePharm® Corporation (OTCQB: MSLP) a leading international, award-winning sports nutrition company. In addition to branding in the hallowed Octagon®, MusclePharm will be featured in a variety of UFC programming elements ranging from national television broadcasts to Pay-Per-Views and across UFC's digital platforms. The sponsorship also involves special events and the use of official marks and logos for consumer retail promotions including a special Octagon-shaped Fight Pack.

MusclePharm Sports Science Center Hosts Top Researchers, Coaches, Practitioners, Students for National Strength and Conditioning Association Event
PR Newswire - Tue Nov 26, 6:30AM CST
MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, recently hosted the National Strength and Conditioning Association (NSCA) Colorado State Clinic which featured leading U.S. researchers and speakers including Dr. Jordan Moon, Colorado State Director, NSCA and Dr. Eric Serrano, Chief Medical Officer, of MusclePharm and Director of the company's Research Institute.

LEVI & KORSINSKY, LLP Notifies Investors of BIOZONE PHARMACEUTICALS, INC. of Claims of Breaches of Fiduciary Duty by Board of the Company in Connection with the Sale of Assets to MusclePharm Corporation
Business Wire - Tue Nov 19, 12:11PM CST
Levi & Korsinsky notifies investors of Biozone Pharmaceuticals, Inc. ("Biozone" or the "Company") (Nasdaq: BZNE) of possible breaches of fiduciary duty and other violations of state law in connection with the sale of Company assets to MusclePharm Corporation ("MusclePharm") (OTCQB: MSLP).

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of the Biozone Pharmaceuticals, Inc. Proposed Asset Sale to MusclePharm Corporation
Business Wire - Tue Nov 19, 7:17AM CST
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether the Board of Directors of Biozone Pharmaceuticals, Inc. (Nasdaq: BZNE) breached its fiduciary duties in connection with the Company's proposed sale of assets to MusclePharm Corporation (OTCQB: MSLP).

MusclePharm's Award Winning Amino 1 To Be Available at Costco January 2014
PR Newswire - Tue Nov 19, 6:30AM CST
MusclePharm Corporation (OTCQB: MSLP) a leading international, award-winning sports nutrition company, announced today that its popular Amino 1 recovery and hydration sports drink will be available at 150 Costco locations nationwide mid-January 2014.

MusclePharm Announces Results of Audit Committee Review - No Restatement Required
Marketwire - Fri Nov 15, 6:00AM CST
MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm", or the "Company"), a leading international, award-winning sports nutrition company, announced today that the Audit Committee of its Board of Directors has reviewed certain matters that are the subject of the SEC investigation disclosed in a Form 8-K filed on September 30, 2013 and concluded that no restatement of prior periods' financial statements is required. The matters reviewed included a loss of $2.1 million recorded in 2011 in regard to settlement of accounts payable, the reserve established for previously disclosed litigation initiated against the Company by William Bossung (the "Bossung Litigation"), six proposed adjustment entries made by the auditors in 2012 which were approved by the Audit Committee (the effect of which were below the materiality threshold of the audit) and not made by the Company in that year, and the amounts disclosed as executive perquisites in the Annual Reports on Form 10-K for the fiscal years ended 2010, 2011 and 2012.

MusclePharm Third Quarter Gross Sales Increased 51% to a Record $31.1 Million
Marketwire - Thu Nov 14, 3:23PM CST
MusclePharm Corporation (OTCQB: MSLP) (the "Company", or "MusclePharm"), a leading international, award-winning sports nutrition company, announced today its financial results for the third quarter ended September 30, 2013 ("Q3 2013").

Exclusive Insight on ITEN, MSLP and AMBS
ACCESSWIRE - Thu Nov 14, 3:20AM CST
CodeSmart Holdings, Inc. (OTC:ITEN), Muscle Pharm Corp. (OTC:MSLP) and Amarantus Bioscience Holdings, Inc (OTC:AMBS) have been added to our watch list.

Biozone Announces First Step in Strategic Transition
Marketwire - Wed Nov 13, 2:19PM CST
Biozone Pharmaceuticals, Inc. (OTCQB: BZNE), a manufacturer of over-the-counter (OTC) pharmaceuticals, and skin care, cosmetic and beauty products, and developer of proprietary drug delivery platforms, issued the following Letter to Shareholders from Elliot Maza, Chief Executive Officer and CFO of the company.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 62

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 299

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 343

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 29

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 123

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 456

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading

Top 5 Most Recently Viewed Articles

Brazil Potash Secures $75 Million Equity Line for Growth

Updated Category News Views 167

Brazil Potash Secures Key Funding for Autazes Project Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE American: GRO), a prominent player in mineral development focused on potash mining, has recently finalized a significant agreement establishing an equity line of credit (ELOC) with Alumni Capital LP. This collaboration signals a crucial step in...

Continue Reading
AGCO Completes Major Strategic Shift Transforming Business Focus

Updated Category News Views 101

AGCO Completes Divestiture of Grain & Protein Business AGCO Corporation (NYSE: AGCO), a leading firm in agricultural machinery and precision ag technology, has finalized the sale of the majority of its Grain & Protein business to American Industrial Partners (AIP) in an all-cash deal valued at around $700 million. This significant transition emphasizes AGCO's focus on...

Continue Reading
Vincent Bouatou Takes the Helm as CTO at IDEMIA Public Security

Updated Category News Views 64

Vincent Bouatou Appointed as Chief Technology Officer With a wealth of experience in the technology sector, Vincent Bouatou has been officially announced as the Chief Technology Officer (CTO) of IDEMIA Public Security. His extensive background in driving technological innovations positions him to make significant strides in the biometric technology industry. Driving...

Continue Reading
MedX Holdings, Inc. Reaches New Heights in Q1 Revenue Growth

Updated Category News Views 171

MedX Holdings, Inc. Reports Extraordinary Q1 Revenue Gains MedX Holdings, Inc. (OTC: MEDH) is delighted to share its impressive financial results for the first quarter of 2025. With record revenue levels and strategic advancements, this milestone reflects the company's commitment to becoming a prominent player in cannabis retail, technology, and franchise development....

Continue Reading
Erste Group Upgrades WW Grainger Stock Amid Positive Outlook

Updated Category News Views 74

Erste Group upgraded WW Grainger (NYSE: GWW) from Hold to Buy back in mid-2024, showing that the desks had a new favorite. With a return on equity at a whopping 59%, Grainger's performance left many competitors in the dust, making it a must-watch stock for anyone looking to get into industrial supply chains. What's Driving the Upgrade? The reasons behind this rating shift...

Continue Reading